

B259 conc id

-40, -42, -43, -50, -52, -55, -56, -58 to -61, -63, -65, and -66 (positions 16, 14, 12, 11, 4 and 2 of SEQ ID NO:6 and positions 22, 21, 19 to 16, 14, 12 and 11 of SEQ ID NO:5, respectively) which correspond to guanine nucleotides in the Sp1-binding site. No protection was seen over these positions on genomic DNA from PMA-stimulated HL60 cells. In contrast, genomic DNAs from IM-9 and Jurkat cells, either unstimulated or PMA-stimulated, were similarly protected over these positions. From these results, we conclude that occupation of the CD11d promoter by Sp1 is significantly reduced in PMA-stimulated myeloid cells, and that myeloid-specific downregulation of CD11d expression is mediated through preferential loss of Sp1 binding following PMA stimulation.

In the Claims:

Please amend the claims to read as follows:

B26

2. (Amended) The promoter of the CD11d gene according to claim 1, wherein the functional portion is selected from the group consisting of 225 to 1244 of SEQ ID NO:1, and 998 to 1244 of SEQ ID NO:1.

B27

6. (Amended) The promoter of the CD11d gene according to claim 5, wherein one of the strands of the DNA hybridizes to all or a functional portion of a sequence selected from the group consisting of 225 to 1244 of SEQ ID NO:1, and 998 to 1244 of SEQ ID NO:1.

B28

8. (Amended) The cis-acting element according to claim 7, wherein the cis-acting element is the 225 to 1244 region of SEQ ID NO:1.

9. (Amended) The cis-acting element according to claim 7, wherein the cis-acting element is the 999 to 1244 region of SEQ ID NO:1.

B28
10. (Amended) The cis-acting element according to claim 7, wherein the cis-acting element is the 1099 to 1131 region of SEQ ID NO:1.

B29
14. (Amended) The cis-acting element according to claim 13, wherein the binding site for Sp1 is the 1108 to 1131 (5') region of SEQ ID NO:1.

B30
16. (Amended) The cis-acting element according to claim 15, wherein the cis-acting element is the 580 to 793 region of SEQ ID NO:1.

A marked up version showing the additions to the claims in bold and underline and deletions from the claims bracketed and in bold is attached at the end of this Amendment.